Clinical Trial Update: A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ACP-196 (acalabrutinib) in recurrent glioblastoma multiforme, a phase 1b/2 open-label study; the trial status is active not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• ACP-196 (acalabrutinib)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-07-29